Patents Examined by Shelly Guest Cermak
  • Patent number: 5684133
    Abstract: The CNS myelin associated proteins inhibit neurite outgrowth in nerve cells and neuroblastoma cells, and can also inhibit fibroblast spreading. Such inhibitory proteins include a 35,000 dalton and a 250,000 dalton molecular weight protein and analogs, derivatives, and fragments thereof. The CNS myelin associated inhibitory proteins may be used in the treatment of malignant tumors. The present invention is also directed to antibodies to the CNS myelin associated proteins; such antibodies can be used in the diagnosis and therapies of nerve damage resulting from trauma, infarction, and degenerative disorders of the central nervous system. In a specific embodiment of the invention, monoclonal antibody IN-1 may be used to promote regeneration of nerve fibers over long distances in spinal cord lesions.
    Type: Grant
    Filed: August 30, 1989
    Date of Patent: November 4, 1997
    Assignee: Erziehungsdirektion of the Canton Zurich
    Inventors: Martin E. Schwab, Pierenrico W. Caroni
  • Patent number: 5545723
    Abstract: A IFN-.beta. mutein in which phe (F), tyr (Y), trp (W) or his (H) is substituted for val (V) at position 101, when numbered in accordance with wild type IFN-.beta., DNA sequences encoding these IFN-.beta. muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an IFN-.beta. mutein, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing IFN-.beta. muteins and methods of using those compositions to treat viral infections, cancer or tumors or for immunomodulation.
    Type: Grant
    Filed: March 15, 1994
    Date of Patent: August 13, 1996
    Assignee: Biogen Inc.
    Inventors: Susan E. Goelz, Richard L. Cate, E. Pingchang Chow, R. Blake Pepinsky
  • Patent number: 5539094
    Abstract: The present invention provides nucleotide sequences encoding proteins and fragments thereof that bind to Bcl-2-related proteins. The invention also provides a Bcl-2-associated protein (BAP) such as Bcl-2-associated protein-1 (BAP-1), which binds to Bcl-2. The invention also provides antibodies that specifically bind to a BAP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BAP such as BAP-1 or Raf-related protein with a Bcl-2-related protein and methods for detecting agents that induce dissociation of a bound complex formed by the association of a BAP and a Bcl-2-related protein. The invention further provides methods for modulating the activity of a Bcl-2-related protein in a cell by introducing into the cell a nucleic acid encoding a BAP or by introducing into the cell an antisense nucleotide sequence, which is complementary to a region of a gene encoding a BAP.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: July 23, 1996
    Assignee: La Jolla Cancer Research Foundation
    Inventors: John C. Reed, Shinichi Takayama, Takaaki Sato
  • Patent number: 5530109
    Abstract: The invention relates to isolated nucleic acid molecules which encode for part or all of glial growth factor molecules, as well as recombinant vectors and transfected cell lines.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: June 25, 1996
    Assignees: Ludwig Institute For Cancer Research, Cambridge Neuroscience
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario S. Chen, Ian Hiles
  • Patent number: 5488099
    Abstract: Neurotrophins having activities of multiple parental neurotrophins are described, as well as DNA for their production and pharmaceutical preparations thereof.
    Type: Grant
    Filed: November 20, 1992
    Date of Patent: January 30, 1996
    Inventors: Hakan B. Persson, deceased, Carlos F. I. Moliner
  • Patent number: 5470952
    Abstract: Heterodimer proteins comprising a soluble .alpha. specificity determining cytokine receptor component and the extracellular domain of a .beta. receptor component function as CNTF and IL-6 antagonsists.
    Type: Grant
    Filed: October 20, 1993
    Date of Patent: November 28, 1995
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Neil Stahl, Aris N. Economides, George D. Yancopoulos
  • Patent number: 5466783
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: November 14, 1995
    Assignees: Monsanto Company, Washington University
    Inventors: Tze-Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • Patent number: 5464943
    Abstract: Disclosed are (1) a mutein of a fibroblast growth factor (FGF), the DNA having introduced therein at least one nucleotide sequence coding for a glycosylation site, (2) a DNA coding for the mutein of (1), (3) a vector containing the DNA of (2), (4) a transformant transformed with the vector of (3), and (5) a process for producing the mutein which comprises cultivating in a culture medium the transformant of a yeast or animal cell transformed with a vector of (3), and producing and accumulating the mutein of (1) in the culture medium, whereby the FGF mutein into which at least one glycosylation site has been introduced is improved in productivity, stability and activities, and advantageously used as medicine.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: November 7, 1995
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Masaharu Senoo, Reiko Sasada, Koichi Igarashi
  • Patent number: 5460811
    Abstract: A cDNA library is constructed using mRNA from human fibroblasts induced with poly(I):poly(C). A bacterial clone containing fibroblast interferon cDNA sequences identified by hybridization to a cDNA probe synthesized using deoxyoligonucleotide primers which hybridize to fibroblast interferon mRNA specifically. Expression plasmids are constructed which permit the synthesis in E. coli of 8.times.10.sup.7 units of human fibroblast interferon per liter of culture. The bacterially produced fibroblast interferon is indistinguishable from authentic human fibroblast interferon by several critieria.
    Type: Grant
    Filed: June 12, 1989
    Date of Patent: October 24, 1995
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Roberto Crea
  • Patent number: 5455338
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: October 3, 1995
    Assignees: ZymoGenetics, Inc., University of New Mexico
    Inventors: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster
  • Patent number: 5451669
    Abstract: A receptor for the Fc portion of immunoglobulin, derived from mouse or human cells, the receptor exhibiting the ability to bind to the Fc portion of mouse and human immunoglobulin and comprising a transmembrane proteins having about 280-301 amino acids including two substantially regularly spaced pairs of Cys residues and two or four potential N-linked glycosylation sites. The present invention also provides for a nucleotide sequence, gene, cDNA clone or a vector containing same capable of encoding the above receptor.
    Type: Grant
    Filed: May 27, 1992
    Date of Patent: September 19, 1995
    Assignee: The University of Melbourne
    Inventors: Ian F. C. McKenzie, Mark P. Hogarth, Margaret L. Hibbs, Bernadette M. Scott, Lisa Bonadonna
  • Patent number: 5444164
    Abstract: A new TGF-.beta. induced gene and protein is described. Treatment of TGF-.beta. growth arrested cells induces the production of a novel gene which encodes a 683 amino acid protein, designated BIG-H3, that contains four homologous repeat regions and which may represent a cell surface recognition molecule. This gene and protein is induced in mammalian cells, and specifically human cells, upon treatment with TGF-.beta., and is shown to inhibit the growth of tumor cells.
    Type: Grant
    Filed: May 4, 1992
    Date of Patent: August 22, 1995
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anthony F. Purchio, John E. Skonier, Michael G. Neubauer
  • Patent number: 5428010
    Abstract: Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm- blooded animals are also disclosed.
    Type: Grant
    Filed: March 18, 1992
    Date of Patent: June 27, 1995
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark J. Murray, James D. Kelly
  • Patent number: 5427781
    Abstract: A lymphokine is taught which can be used to activate and stimulate CD3.sup.+, CD4.sup.+ T cells, as well as Sezary leukemic T cells. The lymphokine can be obtained from mitogen-stimulated peripheral blood mononuclear cells or urine of Sezary Syndrome patients. The lymphokine upregulates interleukin-2 receptors.
    Type: Grant
    Filed: July 2, 1993
    Date of Patent: June 27, 1995
    Assignee: University of Miami
    Inventors: Elaine DeFreitas, J. Todd Abrams
  • Patent number: 5427780
    Abstract: Mullerian Inhibiting Substance (MIS)-like polypeptide are described. The MIS-like polypeptides are useful in the treatment of ovarian cancer and other susceptible cancers.
    Type: Grant
    Filed: October 5, 1992
    Date of Patent: June 27, 1995
    Assignees: Biogen, Inc., The General Hospital Corporation
    Inventors: Richard L. Cate, Patricia K. Donahoe
  • Patent number: 5420243
    Abstract: The invention relates to peptides corresponding to regions of the amino acid sequence of TGF-.beta.1 or TGF-.beta.2 which retain, either in monomeric or polymeric forms, at least some of the biological activity of the respective full length TGF-.beta.. The monomeric form of the peptide derived from TGF-.beta.1 comprises the following amino acid sequence: CVRQLYIDFRKDLGWKWIHEPKGYHANFCLGP (SEQ ID NO: 1). The monomeric form of the peptide derived from TGF-.beta.2 comprises the following amino acid sequence: CLRPLYIDFKRDLGWKWIHEPKGYNANFCAGA (SEQ ID NO: 2). Dimers may be formed via disulfide bonds between the amino-terminal cysteine residues, the carboxy-terminal cysteine residues, or amino- and carboxy-terminal cysteine residues of the monomer subunits.
    Type: Grant
    Filed: January 26, 1993
    Date of Patent: May 30, 1995
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Yasushi Ogawa, David Schmidt
  • Patent number: 5405945
    Abstract: Expression constructs for the alpha subunit common to the four human reproductive hormones are disclosed which have enhanced efficiency. These constructs are characterized by the presence of only one intron interrupting the coding sequence for the alpha subunit.
    Type: Grant
    Filed: September 24, 1992
    Date of Patent: April 11, 1995
    Assignee: Washington University
    Inventors: Irving Boime, Martin M. Matzuk
  • Patent number: 5387520
    Abstract: Disclosed are methods and compositions for treating neuroblastoma cells. The methods include contacting the neuroblastoma cells with a neurotrophic factor and less than a lethal dose of an inhibitor of cell proliferation for about 1 to 15 days, and then maintaining the neuroblastoma cells in contact with the neurotrophic factor for an additional 1 to 15 days. The composition includes a neurotrophic factor such as the neurotropin, nerve growth factor, and an inhibitor of cell proliferation such as aphidicolin, thymidine, or hydroxyurea. Also disclosed are methods for inducing the remission or differentiation of, or eliminating, neuroblastoma cells.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: February 7, 1995
    Assignee: Worcester Foundation for Experimental Biology
    Inventors: Patrizia LoPresti, Wojciech Poluha, Dorota K. Poluha, Alonzo H. Ross
  • Patent number: 5376567
    Abstract: DNA constructs are prepared which operably link human interferon genes, selective, eukaryotic marker genes, and promoter and expression control sequences for the expression of human interferon in Chinese hamster ovary (CHO) cells or progeny thereof. The human recombinant interferon so produced contains glycans which are a subset of the population of glycans which are contained in the native counterpart, and may be used in therapeutic formulations. The CHO cells yield high levels of human interferon with no detectable amounts of host, IFN, either constitutive or inductive.
    Type: Grant
    Filed: January 9, 1992
    Date of Patent: December 27, 1994
    Assignees: Berlex Laboratories, Inc., Board of Trustees of the Leland Stanford, Jr. Univ.
    Inventors: Francis P. McCormick, Michael A. Innis, Gordon M. Ringold
  • Patent number: 5372808
    Abstract: Methods for the treatment of cell proliferation disorders, viral infections, and other conditions without causing significant side effects normally associated with interferon therapy, involving administering to a patient in need thereof a therapeutically effective amount of consensus human leukocyte interferon are disclosed. Also disclosed are pharmaceutical compositions of consensus human leukocyte interferon.
    Type: Grant
    Filed: April 15, 1992
    Date of Patent: December 13, 1994
    Assignee: Amgen Inc.
    Inventors: Lawrence M. Blatt, Milton W. Taylor